Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?

References

• Mohile SG, Epstein RM, Hurria A, Heckler CE, Canin B, Culakova E, Duberstein P, Gilmore N, Xu H, Plumb S, et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute community oncology research program. JAMA Oncol. 2020;6(2):196–204. doi:10.1001/jamaoncol.2019.4728.
   PubMed Web of Science ®Google Scholar
• Presley CJ, Gomes F, Burd CE, Kanesvaran R, Wong ML. Immunotherapy in older adults with cancer. J Clin Oncol. 2021;39(19):2115–27. doi:10.1200/JCO.21.00138.
   PubMed Web of Science ®Google Scholar
• Sedrak MS, Freedman RA, Cohen HJ, Muss HB, Jatoi A, Klepin HD, Wildes TM, Le‐Rademacher JG, Kimmick GG, Tew WP, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin. 2021;71(1):78–92. doi:10.3322/caac.21638.
   PubMed Web of Science ®Google Scholar
• Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254–e262. doi:10.1016/S1470-2045(16)30030-4.
   PubMed Web of Science ®Google Scholar
• Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38(17):1887–96. doi:10.1200/JCO.19.02318.
   PubMed Web of Science ®Google Scholar
• Cortés J, Diéras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, Thuss-Patience P, Allegrini G, De Laurentiis M, Lohrisch C, Oravcová E, et al. Efficacy and safety of trastuzumab emtansine plus capecitabine vs. trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial. JAMA Oncol. 2020;6(8):1203–09. doi:10.1001/jamaoncol.2020.1796.
   PubMed Web of Science ®Google Scholar
• Shitara K, Honma Y, Omuro Y, Yamaguchi K, Chin K, Muro K, Nakagawa S, Kawakami S, Hironaka S, Nishina T, et al. Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a subgroup analysis of the GATSBY study. Asia Pac J Clin Oncol. 2020;16(1):5–13. doi:10.1111/ajco.13243.
   PubMed Web of Science ®Google Scholar
• Yu EY, Petrylak DP, O’Donnell PH, Lee J-L, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial [published correction appears in Lancet Oncol. 2021 Jun;22(6):e239]. Lancet Oncol. 2021;22(6):872–82. doi:10.1016/S1470-2045(21)00094-2.
   PubMed Web of Science ®Google Scholar
• Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee J-L, Matsubara N, Vulsteke C, Castellano D, Wu C, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35. doi:10.1056/NEJMoa2035807.
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–41. doi:10.1056/NEJMoa2028485.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O’Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709–18. doi:10.1016/j.annonc.2020.09.004.
   PubMed Web of Science ®Google Scholar
• Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, et al. Sacituzumab govitecan, a trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746–56. doi:10.1016/j.annonc.2021.03.005.
   PubMed Web of Science ®Google Scholar
• Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, Piette F, Adamson LM, Nagy RJ, Lanman RB, et al. Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10. J Clin Oncol. 2019;37(29):2601–09. doi:10.1200/JCO.19.00858.
   PubMed Web of Science ®Google Scholar
• Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–89. doi:10.1016/S1470-2045(21)00086-3.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21. doi:10.1056/NEJMoa1914510.
   PubMed Web of Science ®Google Scholar
• Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, Chung H-C, Kawakami H, Yabusaki H, Lee J, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30. doi:10.1056/NEJMoa2004413.
   PubMed Web of Science ®Google Scholar
• Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim S-B, Im S-A, Wang Y, Salgado R, Mani A, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–95. doi:10.1016/S1470-2045(20)30465-4.
   PubMed Web of Science ®Google Scholar
• Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, et al. A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol. 2018;13(2):273–79. doi:10.1016/j.jtho.2017.10.032.
   PubMed Web of Science ®Google Scholar
• Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O’Shaughnessy J, Kalinsky K, Guarino M, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35(19):2141–48. doi:10.1200/JCO.2016.70.8297.
   PubMed Web of Science ®Google Scholar
• Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M, Gradishar WJ. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res Treat. 2018;171(2):371–81. doi:10.1007/s10549-018-4792-0.
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [published correction appears in J Clin Oncol. 2013 Aug 10;31(23):2977]. J Clin Oncol. 2013;31(9):1157–63. doi:10.1200/JCO.2012.44.9694.
   PubMed Web of Science ®Google Scholar
• Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, Crivellari D, Fang L, Michelson G, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol. 2014;32(14):1437–44. doi:10.1200/JCO.2013.52.6590.
   PubMed Web of Science ®Google Scholar
• Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O’Shaughnessy J, Moroose RL, Santin AD, Abramson VG, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–51. doi:10.1056/NEJMoa1814213.
   PubMed Web of Science ®Google Scholar
• Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, et al. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur J Cancer. 2019;109:92–102. doi:10.1016/j.ejca.2018.12.022.
   PubMed Web of Science ®Google Scholar
• Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting trop-2, sacituzumab govitecan. Clin Cancer Res. 2017;23(19):5711–19. doi:10.1158/1078-0432.CCR-17-0933.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, Perez EA. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer previously treated with chemotherapy and 2 or more HER2-targeted agents: results from the T-PAS expanded access study. Cancer J. 2015;21(5):357–64. doi:10.1097/PPO.0000000000000144.
   PubMed Web of Science ®Google Scholar
• Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JDC, Garrido P, et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res. 2019;25(1):64–72. doi:10.1158/1078-0432.CCR-18-1590.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino E, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med. 2013 Jun 20;368(25):2442]. N Engl J Med. 2012;367(19):1783–91. doi:10.1056/NEJMoa1209124.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. doi:10.1056/NEJMoa1814017.
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–53. doi:10.1016/S1470-2045(17)30111-0.
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero J-M, Smitt M, Yu R, Leung ACF, Wildiers H. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–99. doi:10.1016/S1470-2045(14)70178-0.
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero J-M, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–54. doi:10.1016/S1470-2045(17)30313-3.
   PubMed Web of Science ®Google Scholar
• Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer. JAMA Oncol. 2018;4(9):1214–20. doi:10.1001/jamaoncol.2018.1812.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Oliveira M, Traina AT, Tolaney SM, Loirat D, Punie K, Hurvitz SA, Lynce F, Hamilton EP, Nanda R, et al. Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of Sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). J of Clin Oncol. 2021 May 28. doi:10.1200/JCO.2021.39.15_suppl.1011.
   PubMed Web of Science ®Google Scholar